Novo Nordisk A/S, a healthcare company, engages in discovering, developing, manufacturing, and marketing pharmaceutical products and services. The company markets its products in approximately 180 countries. Segments The company operates through two business segments, Diabetes Care and Biopharmaceuticals. Diabetes Care This segment covers insulins, GLP-1, other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs, and obesity. In December 2014, the GLP-1 agonist liraglutide was approved in the United States in a 3 mg dose for weight management. The trade name for this product would be Saxenda and launch is planned for the first half of 2015. Biopharmaceuticals This segment covers the therapy areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. Customers The company conducts business with customers in Iran, including the Government of Iran (GOI). In 2014, the company sold its products and devices directly to two GOI-controlled pharmaceutical companies (Exir Pharmaceutical Co. (Exir) and Darou Pakhsh Trade Development Co.) and contracted with two GOI-controlled pharmaceutical manufacturers to fill, formulate, and/or re-pack the company’s certain products (Exir and Darou Pakhsh Pharma. Chem. Co.). Novo Nordisk Pars, a wholly-owned affiliate of the company located in Iran contracts with four GOI-controlled companies (Exir; Darou Pakhsh Trading Co.; Darou Pakhsh Co.; and Hedjat Distribution Co.) to import and distribute its products. NNE Pharmaplan A/S, a wholly-owned affiliate of the company, has a contract with the Iranian Blood Research & Fractionation Company for the engineering, procurement, and construction of a human plasma fractionation plant in Iran for the production of human plasma derivatives. NNE Pharmaplan A/S also has a contract with SOHA Helal Iran Medical Devices Co., a GOI-controlled company, to provide raw materials for dialysis filters. Markets and Distribution The company’s insulin and other pharmaceutical products are marketed and distributed through subsidiaries, distributors, and independent agents with responsibility for specific geographical areas. The primary markets are North America, China, Japan, and the major European countries. Its international operations are in Algeria, Turkey, Australia, India, Argentina, Brazil, and Russia. In addition, the company conducts business with customers in Syria, Sudan, and Cuba. Patents The company’s major delivery devices are protected by various patents of which the first would expire in January 2019. The company holds a formulation patent on NovoLog/NovoRapid, which provides coverage until June 2017 in all major markets. In addition, the company holds a formulation patent on NovoLog Mix/NovoMix in the United States, which provides coverage until June 2017. The company holds two formulation patents on the room temperature stable preparation of NovoSeven, which provides coverage of this formulation until 2023 and 2024, respectively, in all major markets. The expiry of the drug compound patent has had limited impact on the sale of NovoSeven due to the complexity relating to the regulatory pathways for ‘biosimilar’ coagulation factors in the United States, the EU, and Japan. Norditropin is not covered by a drug compound patent. However, the formulation used is covered by a formulation patent that expires in 2017 in the United States, Europe, and Japan. History Novo Nordisk A/S was founded in 1925. The company was incorporated in 1931.
novo nordisk a/s-b (NOVOB:Copenhagen)
Phone: 45 44 44 88 88
Fax: 45 44 49 05 55www.novonordisk.com
|AbbVie Inc||$70.01 USD||-0.15|
|Allergan plc||$331.15 USD||+2.28|
|Amgen Inc||$176.59 USD||+4.90|
|Bristol-Myers Squibb Co||$65.64 USD||+1.18|
|Eli Lilly & Co||$84.51 USD||-0.03|
|View Industry Companies|
Sponsored Financial Commentaries
To contact NOVO NORDISK A/S-B, please visit www.novonordisk.com. Company data is provided by Capital IQ. Please use this form to report any data issues.